{"entity":{"id":"michael-von-bergwelt","kind":"person","name":"Michael von Bergwelt","aka":[],"tldr":"Michael von Bergwelt is a haematologist who leads LMU's cell therapy and immuno-oncology programme.","summary":"Michael von Bergwelt is Director of the Department of Medicine III (Hematology and Oncology) at LMU Klinikum München. A haematologist, his specialisms are haematology, cell therapy and immunotherapy toxicity. He leads LMU's cell therapy and immuno-oncology programme, with research on CAR-T cell therapy, T-cell engaging bispecific antibodies and the management of immune-related toxicities. His department combines clinical haematology and oncology with the delivery of these newer immune therapies. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Bergwelt-Baildon%20M%5BAuthor%5D%20CAR%20T"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","t-cell-engager"],"targets":[],"drugs":[],"companies":[],"institutions":["lmu-munich"],"pathways":[],"terms":["crs"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department of Medicine III (Hematology and Oncology), LMU Munich","institutionId":"lmu-munich","specialisms":["Haematology","Cell therapy","Immunotherapy toxicity"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=von%20Bergwelt-Baildon%20M%5BAuthor%5D%20CAR%20T"}],"papers":[{"title":"Cytokine release syndrome","journal":"Journal for ImmunoTherapy of Cancer","year":2018,"doi":"10.1186/s40425-018-0343-9"},{"title":"Advances in cancer immunotherapy 2019 – latest trends","journal":"Journal of Experimental & Clinical Cancer Research","year":2019,"doi":"10.1186/s13046-019-1266-0"},{"title":"CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition","journal":"Blood","year":2006,"doi":"10.1182/blood-2005-08-3507"}]},"route":"/people/michael-von-bergwelt/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"institution":[{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/"}],"term":[{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"}]}}